Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations

Next Previous
Trial Profile

A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; JSI-1187 (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors JS InnoPharm (Shanghai)

Most Recent Events

  • 01 Feb 2024 Planned End Date changed from 17 Nov 2024 to 17 Dec 2024.
  • 01 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
  • 25 Sep 2023 Planned primary completion date changed from 17 May 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top